AstraZeneca, Ionis report major trial failure with heart disease drug
AstraZeneca and Ionis face a sharp market decline following the failure of a collaborative heart disease drug trial.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
AstraZeneca and Ionis have reported that a clinical trial for their heart disease drug failed to reach its primary objective. The announcement triggered an immediate downturn in both companies' stock values.
Coverage from The Times, Barron's, Bloomberg.com, The Guardian, and STAT highlights the negative impact on the UK stock market. While some analysts referenced in Barron's suggest the market reaction may be an overreaction, the news has also been linked to broader downward pressure on UK equities.
Market observers are monitoring future performance indicators and potential statements from the companies regarding the status of the drug program. Coverage does not yet specify the long-term impact on the development partnership or subsequent clinical milestones.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. Updated just now.
Quick answers
What happened to the heart disease drug?
The trial failed to meet its target objectives according to reports from AstraZeneca and Ionis.
How did the market react?
Shares of both AstraZeneca and Ionis declined following the news, with the former also impacting the broader UK stock market.
Is the drug program cancelled?
Coverage does not yet specify the future status of the drug program.
Coverage (5)
- AstraZeneca shares down as drug trial fails to meet target The Times · 4h ago
- AstraZeneca and Ionis Stocks Sink on Trial Miss and Analysts See an Overreaction Barron's · 4h ago
- Watch AstraZeneca Drug Trial Failure Sends Shares Plunging Bloomberg.com · 4h ago
- Crude oil prices rise again while UK stock market falls, dragged down by AstraZeneca The Guardian · 4h ago
- AstraZeneca, Ionis report major trial failure with heart disease drug STAT · 4h ago
Topics
Related trends
AstraZeneca and Ionis Stocks Sink on Trial Miss and Analysts See an Overreaction
AstraZeneca and Ionis face market volatility following the failure of their heart disease drug, Wainua, in a critical clinical trial.
The 'Magnificent 7' stocks are trading at their cheapest valuation in more than a decade
The 'Magnificent 7' stocks have reached their lowest valuation levels in over ten years, sparking debate over market stability.
Should You Buy Intel Stock Before July 23?
Market analysts and financial outlets are evaluating Intel's stock performance and price positioning ahead of the company's upcoming earnings period.
Famed investor Jeremy Grantham says history will end up laughing at SpaceX, the 'craziest IPO in the history of man' that just joined the Nasdaq 100
SpaceX faces intense market scrutiny following its recent entry into the Nasdaq 100 and sharp criticism from investor Jeremy Grantham.
Dow Jones Futures: Oil Prices Keep Rising On Iran News After Samsung Fans AI Fears
Oil surges, markets jitter as Iran tensions and Fed policy collide—AI resilience tested in the crossfire
Oracle Cloud could top revenue estimates in fiscal 2027, Piper Sandler says (ORCL:NYSE)
Oracle faces divergent market projections as analysts debate the long-term potential of its significant investment in AI data centers.